Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Eloxatin submitted for adjuvant treatment of colon cancer in U.S. and Europe

Jan. 21, 2004

MediGene names Yamanouchi as pan-European partner for prostate cancer products

Jan. 21, 2004

Gefitinib shows promise in the treatment of recurrent glioblastoma

Jan. 21, 2004

Phase III eflornithine trial in superficial bladder cancer discontinued

Jan. 20, 2004

Interim data on the effects of GTI-2040 and capecitabine in advanced renal cell cancer

Jan. 20, 2004

Phase Ib trial evaluates WX-UK1 in head and neck cancer patients

Jan. 19, 2004

Novel protein kinase inhibitors for cancer and neurological disorders

Jan. 19, 2004

Morphotek and NCI sign agreement to develop antibodies for the treatment of various cancers

Jan. 19, 2004

Dosing commenced in phase II adult AML trial of clofarabine

Jan. 16, 2004

SB-715992 enters broad phase II program for cancer

Jan. 16, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...